Grant: CIHR Fellowship
McMaster University
$45,000.00
Randomized Clinical Trial of Propranolol in Severely Burn Patients
FY 2022-23
Summary
Severe burns are a leading cause of death and disability worldwide. Despite advances in patient care, the persistent hypermetabolic stress response characterized by insulin resistance, increased lipid catabolism, and multi-organ dysfunction continues to cause substantial morbidity and mortality. Recently, the adipose tissue has been implicated in the induction and persistence of post-burn hypermetabolism. Two types of body fat, white adipose tissue (WAT) and brown adipose tissue (BAT), exist in humans. WAT acts as an energy reservoir to store excess calories, whereas BAT burns rather than stores excess calories due to increased mitochondrial content and expression of uncoupling protein 1 (UCP1). However, the lines have been blurred with the discovery that a burn injury induces the browning of WAT, a process in which white adipocytes become beige adipocytes and adopt brown-like features (i.e., increased mitochondria and UCP-1 expression). WAT browning activation in burn patients has been implicated in causing insulin resistance, muscle catabolism, hepatic steatosis, and most importantly increased mortality. Unfortunately, therapeutic agents that block this browning response remain non-existent. Interestingly, catecholamines, which are increased 40-fold following a burn injury, have been shown to stimulate WAT browning via activation of Beta adrenergic receptors. Therefore, this project aims to study the therapeutic benefits of Propranolol, a clinically approved Beta adrenergic receptor antagonist, in attenuating catecholamine-induced WAT browning and post-burn hypermetabolism. Using a mix of studies involving both burn patients and an animal model of burn injury, we will also assess the efficacy of propranolol in improving clinical outcomes and organ dysfunction. Overall, this project will advance the discovery of a potentially new treatment drug for post-burn hypermetabolism that will ultimately help improve care, recovery, and outcomes for severely burned patients.
Department
Program
CIHR Fellowship
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
473509
Name
Abdullahi Abdikarim
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Clinical
Prcname2
Health Research Training A - Post-PhD (HTA)
Projecttitle
Randomized Clinical Trial of Propranolol in Severely Burn Patients
Programtype2
Fellowship Programs
Orgnameinp2
McMaster University
Cihramount2
$45,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Adipose Tissue Browning; Brown Adipose Tissue; Burn Trauma; Catecholamines; Hypermetabolism
Abstract
Severe burns are a leading cause of death and disability worldwide. Despite advances in patient care, the persistent hypermetabolic stress response characterized by insulin resistance, increased lipid catabolism, and multi-organ dysfunction continues to cause substantial morbidity and mortality. Recently, the adipose tissue has been implicated in the induction and persistence of post-burn hypermetabolism. Two types of body fat, white adipose tissue (WAT) and brown adipose tissue (BAT), exist in humans. WAT acts as an energy reservoir to store excess calories, whereas BAT burns rather than stores excess calories due to increased mitochondrial content and expression of uncoupling protein 1 (UCP1). However, the lines have been blurred with the discovery that a burn injury induces the browning of WAT, a process in which white adipocytes become beige adipocytes and adopt brown-like features (i.e., increased mitochondria and UCP-1 expression). WAT browning activation in burn patients has been implicated in causing insulin resistance, muscle catabolism, hepatic steatosis, and most importantly increased mortality. Unfortunately, therapeutic agents that block this browning response remain non-existent. Interestingly, catecholamines, which are increased 40-fold following a burn injury, have been shown to stimulate WAT browning via activation of Beta adrenergic receptors. Therefore, this project aims to study the therapeutic benefits of Propranolol, a clinically approved Beta adrenergic receptor antagonist, in attenuating catecholamine-induced WAT browning and post-burn hypermetabolism. Using a mix of studies involving both burn patients and an animal model of burn injury, we will also assess the efficacy of propranolol in improving clinical outcomes and organ dysfunction. Overall, this project will advance the discovery of a potentially new treatment drug for post-burn hypermetabolism that will ultimately help improve care, recovery, and outcomes for severely burned patients.
Competitiondate
202210
Approvedterm2
1 yr 0 mth
Pinamesdelim
Abdullahi, Abdikarim
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $45,000~ $0~